Promakhos Therapeutics
New accelerator entry · 2021-07-22 · the record
In their words
We are building a platform of bacterial molecules to awaken our body’s innate ability to control inflammation and heal. Our first indication is Crohn’s Disease, which affects over 500,000 Americans at an annual cost of $10B. After Crohn's disease, we are going for type 1 Diabetes and Multiple Sclerosis.
What the record says
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Promakhos Therapeutics
- Source Check — verify what Promakhos Therapeutics states, against the registers that hold it.
- INVEST — size up this company on the figures its record states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Promakhos Therapeutics for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Promakhos TherapeuticsYou get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Promakhos Therapeutics: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. FoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.